Immunomedics Inc said it filed aregistration statement with the Securities and ExchangeCommission for the proposed sale of 2,500,000 shares of commonstock.    The company said it will sell 2,100,000 shares and thatcertain stockholders will sell the remaining 400,000 shares.    Proceeds from the offering will be used for productdevelopment, basic research, staff expansion, prepayment ofdebt, capital expenditures and working capital, the companysaid. The offering will be co-managed by E.F. Hutton and Co Incand First Boston Corp, Immunomedics said. Reuter&#3;